Structural heart malformations in lupus pregnancy, and a more honest reading of congenital heart block

Design

systematic review and random-effects meta-analysis with meta-regression and subgroup analysis

Population

53 studies, 33,694 pregnancies in women with systemic lupus erythematosus, literature to January 2026

Primary outcome

pooled incidence of structural cardiovascular malformations and congenital heart block in offspring

Effect

structural malformations 3.29% (95% CI 2.48-4.21), OR against controls 3.52 (2.13-5.81) unadjusted and 1.70 (1.22-2.36) adjusted; congenital heart block 1.29% (0.82-1.88), 2.64% where mothers were anti-SSA/Ro positive

Fifty-three studies and 33,694 pregnancies in women with systemic lupus erythematosus were pooled to separate two outcomes that are often discussed together and are not the same thing: structural cardiovascular malformation, and congenital heart block.

Pooled incidence was 3.29% (95% CI 2.48-4.21) for structural malformations and 1.29% (0.82-1.88) for congenital heart block. Against healthy controls, offspring of mothers with lupus had an odds ratio of 3.52 (2.13-5.81) for structural malformations - which fell to 1.70 (1.22-2.36) when only the five studies with multivariable adjustment were pooled. Active disease was associated with structural malformations in meta-regression (P=0.024). For congenital heart block, the picture was different: prevalence was 2.64% in studies where cases were in anti-SSA/Ro-positive mothers against 0.63% in studies not reporting antibody status (P for interaction <0.001), and the comparative risk estimate against controls was described by the authors as elevated but highly imprecise and statistically unstable.

That last sentence is the useful one. Congenital heart block is a rare-event outcome driven by anti-Ro antibody status, not by the lupus label, and pooling studies that do not report antibody status produces a number that means nothing. The counselling that follows is specific: the risk conversation with a woman with lupus depends on whether she is anti-Ro positive, and on whether her disease is active - not on the diagnosis alone.

• Check and document anti-SSA/Ro and anti-La/SSB status before pregnancy in every woman with lupus - the heart block risk tracks the antibody, not the diagnosis
• Aim for quiescent disease before conception; active disease was associated with structural malformations
• Arrange fetal echocardiography according to antibody status and previous obstetric history rather than routinely for all
• Counsel structural malformation risk at around 3%, and say that the independent contribution of lupus itself is uncertain
• Review medication exposure separately - it is one of the confounders these studies could not adjust for

Why it matters

It separates a risk that belongs to an antibody from a risk that belongs to a diagnosis, which changes who needs fetal cardiac surveillance.

Don't overread it

Pooled observational studies with incomplete adjustment for antibody status, disease activity, drug exposure and surveillance intensity - the independent effect of lupus remains uncertain.

The statistics, in plain English

The gap between the unadjusted odds ratio of 3.52 and the adjusted 1.70 is the whole story of this meta-analysis: most of the apparent risk was explained by things measured alongside lupus rather than by lupus. Even 1.70 rests on only five studies with incomplete and inconsistent adjustment, so it is an upper bound rather than an estimate. For congenital heart block the authors decline to give a usable comparative figure at all, which is the correct response when events are rare and the key variable - antibody status - is missing from half the studies.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.